Participated in Tempo Therapeutics' oversubscribed $14.5M financing, led by Galaxy Sirius Partners, to advance its MAP regenerative biomaterial platform.
Tempo Therapeutics is pioneering a new era in tissue engineering biotechnology, utilizing MAP technology to build functional tissue and organs within patients to treat diseases, particularly in surgical oncology
Tempo Therapeutics is pioneering a new era in tissue engineering biotechnology, utilizing MAP technology to build functional tissue and organs within patients to treat diseases, particularly in surgical oncology.